TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY
Women with cervical cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age
- Stage IVB, recurrent or persistent cervical cancer
- After at least 1 line of prior therapy
- Adequate hematologic and organ function
- No active infection
You may NOT participate in this study if you:
- Have planned surgery during the study
- Have active tuberculosis or leptomeningeal disease
- Have known immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
- Are pregnant or breastfeeding
Contact Information
Martina Kracikova, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, NY 10029
Phone: (212) 824-7859
Email: Martina.kracikova@MSSM.EDU